Man­u­fac­tur­ing roundup: AGC Bi­o­log­ics to man­u­fac­ture di­a­betes ther­a­py; Cam­brex caps ac­qui­si­tion of Snap­drag­on Chem­istry

The Wash­ing­ton-based CD­MO AGC Bi­o­log­ics has been tapped to man­u­fac­ture the type 1 di­a­betes treat­ment Tzield from Proven­tion Bio.

AGC Bi­o­log­ics will pro­duce Tzield at …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER